- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Interventions
- erlotinib hydrochloride, docetaxel, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 592
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- sorafenib tosylate, cisplatin, docetaxel, Correlative Studies
- Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
- Interventions
- GB1211, Pembrolizumab, Placebo
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Head and Neck Cancer
- Interventions
- biologic sample preservation procedure, medical chart review
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2050
- U.S. locations
- 4
- States / cities
- Nashville, Tennessee
- Conditions
- Head and Neck Cancer, Carcinoma, Squamous
- Interventions
- Oxaliplatin, Docetaxel, Cetuximab
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Head and Neck Neoplasms
- Interventions
- Monalizumab, Cetuximab, Anti-PD(L)1
- Biological
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 9
- States / cities
- La Jolla, California • Stanford, California • Chicago, Illinois + 5 more
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
- Interventions
- NX-1607, Paclitaxel
- Drug
- Lead sponsor
- Nurix Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Head and Neck Cancer
- Interventions
- Docetaxel, OSI-774, Cisplatin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Esophageal Cancer
- Interventions
- cetuximab, cisplatin, irinotecan hydrochloride, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 132
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 84 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer, Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- Duvelisib, Docetaxel
- Drug
- Lead sponsor
- Kartik Sehgal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- Livmoniplimab, Budigalimab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 21
- States / cities
- Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
- Conditions
- Head and Neck Cancer
- Interventions
- radiation therapy
- Radiation
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Loma Linda, California • Tampa, Florida
- Conditions
- Neoplasms
- Interventions
- BI 765179, Ezabenlimab, Pembrolizumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more
- Conditions
- Malignant Neoplasm
- Interventions
- MK-4700, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Hackensack, New Jersey • San Antonio, Texas
- Conditions
- Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
- Interventions
- enadenotucirev, nivolumab
- Biological
- Lead sponsor
- Akamis Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Duarte, California • Santa Monica, California + 3 more
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Lymphoma, Nausea, Vomiting, Neuroblastoma, Ovarian Cancer, Sarcoma
- Interventions
- electroacupuncture therapy, sham intervention, quality-of-life assessment
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 5 Years to 35 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
- Interventions
- PF-08046032, Sasanlimab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- San Antonio, Texas • Seattle, Washington
- Conditions
- Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
- Interventions
- Gabapentin
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Esophageal Cancer
- Interventions
- ZD1839
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more
- Conditions
- Anorexia, Cachexia, Head and Neck Cancer, Quality of Life
- Interventions
- megestrol acetate, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Epacadostat, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacodynamic Study
- Drug · Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Duarte, California • South Pasadena, California • West Covina, California
- Conditions
- Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
- Interventions
- MEDI4736, MEDI4736 + Tremelimumab, Standard of Care
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 96 Years
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Fullerton, California • Los Angeles, California + 18 more
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo
- Biological · Drug
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 7
- States / cities
- Anaheim, California • Orange, California • Denver, Colorado + 4 more